DaVita's Q1 beat expectations, driven by positive volume mix and strong labor productivity. Management raised full-year guidance, incorporating the benefit of patients transferring from Fresenius clinic closures and better underlying mortality. While noting a favorable trend in ACA exchange enrollment, management remains cautious on the mix impact from lower-tier plan choices. Raised FY2026 adjusted operating income guidance to $2.15-2.25B and EPS to $14.10-15.20.
Buzzberg 분석Raised full-year volume growth to 25-50 bpsDaVita's Q1 beat expectations, driven by positive volume mix and strong labor productivity. Management raised full-year guidance, incorporating the benefit of patients transferring from Fresenius clinic closures and better underlying mortality. While noting a favorable trend in ACA exchange enrollment, management remains cautious on the mix impact from lower-tier plan choices. Raised FY2026 adjusted operating income guidance to $2.15-2.25B and EPS to $14.10-15.20.전체 분석 보기분석 접기
DaVita's Q1 beat expectations, driven by positive volume mix and strong labor productivity. Management raised full-year guidance, incorporating the benefit of patients transferring from Fresenius clinic closures and better underlying mortality. While noting a favorable trend in ACA exchange enrollment, management remains cautious on the mix impact from lower-tier plan choices. Raised FY2026 adjusted operating income guidance to $2.15-2.25B and EPS to $14.10-15.20.
Raised FY2026 treatment volume growth forecast to +25-50bps, with half attributed to patient transfers from Fresenius clinic closures.
Q1 adjusted operating income of $482M included ~$25M in favorable timing.
Maintained FY2026 revenue per treatment growth outlook of 1-2%, expecting commercial mix pressure in the back half.
Revenue$3.4155B
-6% QoQ
EPS$2.87
-16% QoQ
Gross margin31.42%
reported
Op margin14.11%
reported
이번 분기에 달라진 점
01
Guidance
Raised full-year volume growth to 25-50 bps
Guidance tone
02
Demand
Fresenius clinic closures adding treatment volume
Management expressed confidence in their performance and outlook, raising guidance and highlighting strong execution and technology investments.
03
Guidance
Raising adjusted operating income and EPS guidance
Guidance tone
04
Macro
ACA headwind trending favorable but uncertain
Q1 adjusted operating income of $482M included ~$25M in favorable timing.
AI, 자본지출 및 수요 분석
AI
플랫폼 및 수익화
Management discussed a disciplined AI strategy with two parts: modernized data infrastructure and deploying AI solutions across clinical, operational, and business use cases. Examples include ScheduleHub for dynamic scheduling, which is expected to reduce administrative burden and enhance teammate experience. They expect to outperform clinically and operationally as technology evolves.
수요
수주 및 전환
Fresenius clinic closures adding treatment volume. Management expressed confidence in their performance and outlook, raising guidance and highlighting strong execution and technology investments.
자본지출
투자 및 생산능력
The company is investing in IT systems and digital infrastructure, with G&A growth of 13% year-over-year due to continued technology investment. The investments are intended to empower clinical teams and serve as a backbone for future clinical and operational excellence.
톤 · Confident
Management expressed confidence in their performance and outlook, raising guidance and highlighting strong execution and technology investments.
공급망 알파
A1
DaVita expects to gain dialysis patients from Fresenius clinic closures, with half arriving in Q1 and most of the rest in Q2, contributing positively to 2026 volume growth.
“I would guess about half the new starts from Fresenius that we would see by the end of the first quarter. We would guess the other half will come in Q2.”
DaVita's Q1 revenue per treatment (RPT) got a one-time boost from timing, but the company expects commercial mix pressure from ACA enhanced premium tax credit expiration later in the year, moderating full-year RPT growth to 1-2%.
“What we would expect is commercial NICs to decline over the course of the year, and that will put pressure on RPT...”
DaVita expects to gain dialysis patients from Fresenius clinic closures, with half arriving in Q1 and most of the rest in Q2, contributing positively to 2026 volume growth. — Fresenius's network rationalization is ceding market share to DaVita, a direct transfer of volume and revenue.
“Census also benefited from patient transfers in related to ongoing clinic closures by Fresenius.”
… This balanced out performance reflects the strength of our team and our focus on consistent execution. I'll touch on a couple of key metrics that contribute to the quarter and will help shape the remainder of the year. Starting with volume. In the first quarter, our treatment volume was slightly ahead of forecast. Quarter end census was ahead of plan as a result of better than forecasted mortality. partially offset by lower than forecasted admits. Census also benefited from patient transfers in related to ongoing clinic closures by Fresenius. Although negligible in the first quarter volume, we anticipate that these transfers will contribute to positive treatment growth over the remainder of the year. As a result, we're raising our volume growth expectations for the full year from flat to a range of 25 to 50 basis point increase. Approximately half of the increase is from better underlying performance and half is related to transfer in from Fresenius. Switching to labor, Q1 was ahead of plan, primarily from better productivity, which we expect to sustain over the balance of the year. Let me turn to our technology strategy and the investments we're making to strengthen …
Berkshire Hathaway sold a block of DaVita shares back to the company, a capital allocation event with no new information about Berkshire's broader business.
“...which includes the shares bought from Berkshire Hathaway pursuant to our repurchase agreement.”